Efficacy of regorafenib in acute pulmonary carcinomatous lymphangitis as a manifestation of rectal cancer: A case report

Recent therapeutic advancements have prolonged the survival duration of patients with metastatic or recurrent colorectal cancer even during salvage treatment. Although treatment with regorafenib and trifluridine/tipiracil combination has exhibited apparent survival benefits, clear and objective evid...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2019-12, Vol.18 (6), p.6469-6474
Main Authors: Takeuchi, Nobumichi, Koike, Kumiko, Yoshida, Sonomi, Fujiwara, Masayuki
Format: Article
Language:English
Subjects:
Cancer therapies
Case reports
Chemotherapy
Colorectal cancer
Dyspnea
Hematology
Hospitals
Inhibitor drugs
Lung cancer
Medical prognosis
Metastasis
NMR
Nuclear magnetic resonance
Oncology
Patients
Permeability
Respiratory failure
Studies
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c382t-55e4976d9e6ead9f0e09c032df1e10b539300f06fe9a3ebace3a062fa8df1dc83
cites cdi_FETCH-LOGICAL-c382t-55e4976d9e6ead9f0e09c032df1e10b539300f06fe9a3ebace3a062fa8df1dc83
container_end_page 6474
container_issue 6
container_start_page 6469
container_title Oncology letters
container_volume 18
creator Takeuchi, Nobumichi
Koike, Kumiko
Yoshida, Sonomi
Fujiwara, Masayuki
description Recent therapeutic advancements have prolonged the survival duration of patients with metastatic or recurrent colorectal cancer even during salvage treatment. Although treatment with regorafenib and trifluridine/tipiracil combination has exhibited apparent survival benefits, clear and objective evidence of a response to these drugs is scarce. Herein, the present study reports the case of a patient with rectal cancer refractory to multiple surgical interventions and standard chemotherapy. Treatment with regorafenib resulted in immediate improvement of respiratory failure caused by pulmonary lymphangitic carcinomatosis. This improvement persisted for over 3 months and was confirmed by radiology. Our findings suggest that regorafenib can reduce peritumoral edema via its interaction with the vascular endothelial growth factor receptor. Thus, regorafenib functions as a multityrosine kinase inhibitor to alleviate symptoms of lymphangitic carcinomatosis despite the low potency of the drug.
doi_str_mv 10.3892/ol.2019.11043
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6876333</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2323376152</sourcerecordid><originalsourceid>FETCH-LOGICAL-c382t-55e4976d9e6ead9f0e09c032df1e10b539300f06fe9a3ebace3a062fa8df1dc83</originalsourceid><addsrcrecordid>eNpVkU2LFDEQhoMo7jLu0asEPPeYj-l04kFYlvUDFrzoOdSkK7NZupM2SYvz780666BFQYrKkzdVvIS85mwrtRHv0rQVjJst52wnn5FLPhjRcabF83M97C7IVSkPrEWvuNbqJbmQXLOBK3NJft16Hxy4I02eZjykDB5j2NMQKbi1Il3WaU4R8pE6yC7ENENNa6HTcV7uIR5CDYVCSzpDDB5LhRpSPOm5ClN7Fx3m9_S6VQVbd0m5viIvPEwFr57ODfn-8fbbzefu7uunLzfXd52TWtSu73FnBjUaVAij8QyZcUyK0XPkbN9LIxnzTHk0IHEPDiUwJTzoRoxOyw35cNJd1v2Mo8NYM0x2yWFuO9kEwf5_E8O9PaSfVulByRYb8vZJIKcfa1vPPqQ1xzazFVJIOSjei0Z1J8rlVEpGf_6BM_volU2TffTK_vGq8W_-HetM_3VG_gYne5LG</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2323376152</pqid></control><display><type>article</type><title>Efficacy of regorafenib in acute pulmonary carcinomatous lymphangitis as a manifestation of rectal cancer: A case report</title><source>PubMed Central</source><creator>Takeuchi, Nobumichi ; Koike, Kumiko ; Yoshida, Sonomi ; Fujiwara, Masayuki</creator><creatorcontrib>Takeuchi, Nobumichi ; Koike, Kumiko ; Yoshida, Sonomi ; Fujiwara, Masayuki</creatorcontrib><description>Recent therapeutic advancements have prolonged the survival duration of patients with metastatic or recurrent colorectal cancer even during salvage treatment. Although treatment with regorafenib and trifluridine/tipiracil combination has exhibited apparent survival benefits, clear and objective evidence of a response to these drugs is scarce. Herein, the present study reports the case of a patient with rectal cancer refractory to multiple surgical interventions and standard chemotherapy. Treatment with regorafenib resulted in immediate improvement of respiratory failure caused by pulmonary lymphangitic carcinomatosis. This improvement persisted for over 3 months and was confirmed by radiology. Our findings suggest that regorafenib can reduce peritumoral edema via its interaction with the vascular endothelial growth factor receptor. Thus, regorafenib functions as a multityrosine kinase inhibitor to alleviate symptoms of lymphangitic carcinomatosis despite the low potency of the drug.</description><identifier>ISSN: 1792-1074</identifier><identifier>EISSN: 1792-1082</identifier><identifier>DOI: 10.3892/ol.2019.11043</identifier><identifier>PMID: 31807169</identifier><language>eng</language><publisher>Greece: Spandidos Publications UK Ltd</publisher><subject>Cancer therapies ; Case reports ; Chemotherapy ; Colorectal cancer ; Dyspnea ; Hematology ; Hospitals ; Inhibitor drugs ; Lung cancer ; Medical prognosis ; Metastasis ; NMR ; Nuclear magnetic resonance ; Oncology ; Patients ; Permeability ; Respiratory failure ; Studies ; Targeted cancer therapy</subject><ispartof>Oncology letters, 2019-12, Vol.18 (6), p.6469-6474</ispartof><rights>Copyright: © Takeuchi et al.</rights><rights>Copyright Spandidos Publications UK Ltd. 2019</rights><rights>Copyright: © Takeuchi et al. 2019</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c382t-55e4976d9e6ead9f0e09c032df1e10b539300f06fe9a3ebace3a062fa8df1dc83</citedby><cites>FETCH-LOGICAL-c382t-55e4976d9e6ead9f0e09c032df1e10b539300f06fe9a3ebace3a062fa8df1dc83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6876333/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6876333/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31807169$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Takeuchi, Nobumichi</creatorcontrib><creatorcontrib>Koike, Kumiko</creatorcontrib><creatorcontrib>Yoshida, Sonomi</creatorcontrib><creatorcontrib>Fujiwara, Masayuki</creatorcontrib><title>Efficacy of regorafenib in acute pulmonary carcinomatous lymphangitis as a manifestation of rectal cancer: A case report</title><title>Oncology letters</title><addtitle>Oncol Lett</addtitle><description>Recent therapeutic advancements have prolonged the survival duration of patients with metastatic or recurrent colorectal cancer even during salvage treatment. Although treatment with regorafenib and trifluridine/tipiracil combination has exhibited apparent survival benefits, clear and objective evidence of a response to these drugs is scarce. Herein, the present study reports the case of a patient with rectal cancer refractory to multiple surgical interventions and standard chemotherapy. Treatment with regorafenib resulted in immediate improvement of respiratory failure caused by pulmonary lymphangitic carcinomatosis. This improvement persisted for over 3 months and was confirmed by radiology. Our findings suggest that regorafenib can reduce peritumoral edema via its interaction with the vascular endothelial growth factor receptor. Thus, regorafenib functions as a multityrosine kinase inhibitor to alleviate symptoms of lymphangitic carcinomatosis despite the low potency of the drug.</description><subject>Cancer therapies</subject><subject>Case reports</subject><subject>Chemotherapy</subject><subject>Colorectal cancer</subject><subject>Dyspnea</subject><subject>Hematology</subject><subject>Hospitals</subject><subject>Inhibitor drugs</subject><subject>Lung cancer</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>Oncology</subject><subject>Patients</subject><subject>Permeability</subject><subject>Respiratory failure</subject><subject>Studies</subject><subject>Targeted cancer therapy</subject><issn>1792-1074</issn><issn>1792-1082</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpVkU2LFDEQhoMo7jLu0asEPPeYj-l04kFYlvUDFrzoOdSkK7NZupM2SYvz780666BFQYrKkzdVvIS85mwrtRHv0rQVjJst52wnn5FLPhjRcabF83M97C7IVSkPrEWvuNbqJbmQXLOBK3NJft16Hxy4I02eZjykDB5j2NMQKbi1Il3WaU4R8pE6yC7ENENNa6HTcV7uIR5CDYVCSzpDDB5LhRpSPOm5ClN7Fx3m9_S6VQVbd0m5viIvPEwFr57ODfn-8fbbzefu7uunLzfXd52TWtSu73FnBjUaVAij8QyZcUyK0XPkbN9LIxnzTHk0IHEPDiUwJTzoRoxOyw35cNJd1v2Mo8NYM0x2yWFuO9kEwf5_E8O9PaSfVulByRYb8vZJIKcfa1vPPqQ1xzazFVJIOSjei0Z1J8rlVEpGf_6BM_volU2TffTK_vGq8W_-HetM_3VG_gYne5LG</recordid><startdate>20191201</startdate><enddate>20191201</enddate><creator>Takeuchi, Nobumichi</creator><creator>Koike, Kumiko</creator><creator>Yoshida, Sonomi</creator><creator>Fujiwara, Masayuki</creator><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20191201</creationdate><title>Efficacy of regorafenib in acute pulmonary carcinomatous lymphangitis as a manifestation of rectal cancer: A case report</title><author>Takeuchi, Nobumichi ; Koike, Kumiko ; Yoshida, Sonomi ; Fujiwara, Masayuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c382t-55e4976d9e6ead9f0e09c032df1e10b539300f06fe9a3ebace3a062fa8df1dc83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Cancer therapies</topic><topic>Case reports</topic><topic>Chemotherapy</topic><topic>Colorectal cancer</topic><topic>Dyspnea</topic><topic>Hematology</topic><topic>Hospitals</topic><topic>Inhibitor drugs</topic><topic>Lung cancer</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>Oncology</topic><topic>Patients</topic><topic>Permeability</topic><topic>Respiratory failure</topic><topic>Studies</topic><topic>Targeted cancer therapy</topic><toplevel>online_resources</toplevel><creatorcontrib>Takeuchi, Nobumichi</creatorcontrib><creatorcontrib>Koike, Kumiko</creatorcontrib><creatorcontrib>Yoshida, Sonomi</creatorcontrib><creatorcontrib>Fujiwara, Masayuki</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Takeuchi, Nobumichi</au><au>Koike, Kumiko</au><au>Yoshida, Sonomi</au><au>Fujiwara, Masayuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of regorafenib in acute pulmonary carcinomatous lymphangitis as a manifestation of rectal cancer: A case report</atitle><jtitle>Oncology letters</jtitle><addtitle>Oncol Lett</addtitle><date>2019-12-01</date><risdate>2019</risdate><volume>18</volume><issue>6</issue><spage>6469</spage><epage>6474</epage><pages>6469-6474</pages><issn>1792-1074</issn><eissn>1792-1082</eissn><abstract>Recent therapeutic advancements have prolonged the survival duration of patients with metastatic or recurrent colorectal cancer even during salvage treatment. Although treatment with regorafenib and trifluridine/tipiracil combination has exhibited apparent survival benefits, clear and objective evidence of a response to these drugs is scarce. Herein, the present study reports the case of a patient with rectal cancer refractory to multiple surgical interventions and standard chemotherapy. Treatment with regorafenib resulted in immediate improvement of respiratory failure caused by pulmonary lymphangitic carcinomatosis. This improvement persisted for over 3 months and was confirmed by radiology. Our findings suggest that regorafenib can reduce peritumoral edema via its interaction with the vascular endothelial growth factor receptor. Thus, regorafenib functions as a multityrosine kinase inhibitor to alleviate symptoms of lymphangitic carcinomatosis despite the low potency of the drug.</abstract><cop>Greece</cop><pub>Spandidos Publications UK Ltd</pub><pmid>31807169</pmid><doi>10.3892/ol.2019.11043</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1792-1074
ispartof Oncology letters, 2019-12, Vol.18 (6), p.6469-6474
issn 1792-1074
1792-1082
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6876333
source PubMed Central
subjects Cancer therapies
Case reports
Chemotherapy
Colorectal cancer
Dyspnea
Hematology
Hospitals
Inhibitor drugs
Lung cancer
Medical prognosis
Metastasis
NMR
Nuclear magnetic resonance
Oncology
Patients
Permeability
Respiratory failure
Studies
Targeted cancer therapy
title Efficacy of regorafenib in acute pulmonary carcinomatous lymphangitis as a manifestation of rectal cancer: A case report
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T05%3A43%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20regorafenib%20in%20acute%20pulmonary%20carcinomatous%20lymphangitis%20as%20a%20manifestation%20of%20rectal%20cancer:%20A%20case%20report&rft.jtitle=Oncology%20letters&rft.au=Takeuchi,%20Nobumichi&rft.date=2019-12-01&rft.volume=18&rft.issue=6&rft.spage=6469&rft.epage=6474&rft.pages=6469-6474&rft.issn=1792-1074&rft.eissn=1792-1082&rft_id=info:doi/10.3892/ol.2019.11043&rft_dat=%3Cproquest_pubme%3E2323376152%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c382t-55e4976d9e6ead9f0e09c032df1e10b539300f06fe9a3ebace3a062fa8df1dc83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2323376152&rft_id=info:pmid/31807169&rfr_iscdi=true